Published
June 12, 2026
Updated
July 4, 2026
If you took Ozempic, Wegovy, or Mounjaro and had a serious gastrointestinal injury, here is where the federal GLP-1 lawsuits stand — there is no settlement or claim form, only individual cases.
Allegations Only · No Settlement Yet
This article describes pending products-liability lawsuits. The statements below are unproven allegations. Novo Nordisk and Eli Lilly have not been found liable, no class has been certified, and there is no settlement or claim form at this time. This page is informational and is not legal advice.
What Is MDL No. 3094?
MDL No. 3094, captioned In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, is the federal multidistrict litigation consolidating personal-injury lawsuits that allege GLP-1 receptor agonist drugs caused serious gastrointestinal injuries. The proceeding is pending in the U.S. District Court for the Eastern District of Pennsylvania before Judge Karen Spencer Marston, under master docket 24-md-3094.The Judicial Panel on Multidistrict Litigation centralized the litigation on February 2, 2024, when it identified 37 related actions pending across 15 districts. The case was originally assigned to Judge Gene E.K. Pratter and was reassigned to Judge Marston in mid-2024 after Judge Pratter's death. Since then, the docket has grown more than a hundredfold: the JPML's monthly statistics reports show 3,848 actions now pending as of July 1, 2026, keeping MDL 3094 among the largest active MDLs in the federal courts by pending actions. And new cases are still being filed: JPML reports show the pending count climbing from 3,363 on April 1, 2026 to 3,636 on May 1, 3,763 on June 1, and 3,848 on July 1 — roughly 85 to 275 new federal filings per month through the spring and early summer.
That figure is a JPML case-count metric — the number of active pending lawsuits in the MDL — not a docket entry number. Each lawsuit in the MDL remains an individual personal-injury case; the MDL consolidates them only for pretrial proceedings.
Status
Pretrial — Expert & Summary-Judgment Phase
Rule 702 hearing set for September 10–18, 2026 · no bellwether trial date
Cases Pending
3,848 federal actions
JPML statistics, July 1, 2026 · up from 3,763 on June 1 · grew from 37 at centralization
Can I Claim?
No claim form — individual lawsuits only
No settlement or certified class · attorneys are accepting injury cases for individual filing
Which Drugs and Defendants Are Included?
The MDL covers the major GLP-1 receptor agonist drugs prescribed for type 2 diabetes and weight management. Court materials identify Ozempic, Wegovy, and Rybelsus (semaglutide), plus Victoza and Saxenda (liraglutide), as Novo Nordisk products within the litigation, and Trulicity (dulaglutide) plus Mounjaro and Zepbound (tirzepatide) as Eli Lilly products.The court-approved short-form complaint names four default defendants: Novo Nordisk Inc., Novo Nordisk A/S, Eli Lilly and Company, and Lilly USA, LLC. The litigation is aimed at the manufacturers — pharmacies are not standard defendants in the court-approved pleadings, and a set of additional Novo-affiliated entities was dismissed without prejudice in July 2024.
One important distinction: vision-loss claims are not part of MDL 3094. In December 2025, the JPML created a separate proceeding, MDL No. 3163, for claims alleging NAION (non-arteritic anterior ischemic optic neuropathy) and other vision loss tied to GLP-1 drugs — a much smaller docket of 110 pending actions as of June 1, 2026. We cover that litigation separately in our Ozempic eye problems and vision loss lawsuit report. MDL 3094 is the gastrointestinal-injury MDL.
What Plaintiffs Allege in the GLP-1 Lawsuits
Plaintiffs allege that the GLP-1 drugs caused gastrointestinal injuries including gastroparesis (stomach paralysis), ileus, intestinal obstruction or pseudo-obstruction, ischemic bowel, pancreatitis, gallbladder injury, aspiration, micronutrient deficiency, and in some cases death — and that the manufacturers failed to adequately warn patients and physicians of those risks. These are litigated allegations, not court findings of causation. GLP-1 drugs are FDA-approved medications, and their labels have long warned of at least some gastrointestinal side effects such as nausea and vomiting; plaintiffs contend conditions like gastroparesis were not specifically warned about.The original master complaint, filed in November 2024, asserted 17 causes of action, including failure to warn, breach of warranty, fraud and misrepresentation, consumer-protection violations, design defect, negligence, negligent undertaking, wrongful death, loss of consortium, and survival claims. After the court's August 15, 2025 ruling on the manufacturers' motion to dismiss, the operative short-form complaint reorganized the claim menu into 16 selectable counts. The August 2025 opinion let warranty and negligent-undertaking claims proceed, narrowed the fraud theories, required amendment of consumer-protection and certain product-liability claims, and dismissed the request for medical monitoring with leave to amend.
If you believe you experienced gastroparesis or another serious gastrointestinal injury after taking one of these medications, see our weight loss drug stomach paralysis investigation page.
Key Rulings and Timeline in MDL 3094
• February 2, 2024 — The JPML centralizes 37 federal actions in the Eastern District of Pennsylvania.• Mid-2024 — The case is reassigned to Judge Karen Spencer Marston following Judge Pratter's death; plaintiffs' leadership is appointed and direct filing into the MDL is authorized.
• August 2024 — Case Management Order 18 prioritizes three cross-cutting issues: how gastroparesis is reliably diagnosed, warning-label adequacy and federal preemption, and general causation.
• October 2024 — The court declines to order early marketing discovery, holding that label-adequacy and preemption questions come first.
• November 13, 2024 — Plaintiffs file the master complaint with 17 causes of action.
• December 2024 — The JPML confirms Saxenda cases belong in MDL 3094.
• August 15, 2025 — Judge Marston issues the MDL's most consequential merits ruling to date, deciding the motion to dismiss the master complaint in part.
• September–October 2025 — An amended master complaint is filed and the court adopts the short-form complaint structure.
• January 2026 — The court creates a streamlined secondary docket (01-md-3094) for key orders and motions.
• April 30, 2026 — Case Management Order 32 sets Rule 702 (expert-challenge) and summary-judgment deadlines on preemption, warnings, and general causation.
• September 10–18, 2026 — The court has reserved these dates for the Rule 702 hearing.
The Biggest Legal Issues Facing the Court
Preemption and FDA Warning Labels
Because the case involves brand-name prescription drugs with FDA-approved labels, a central question is whether federal law preempts the state-law failure-to-warn claims. Under the Supreme Court's decisions in Wyeth v. Levine and Merck Sharp & Dohme Corp. v. Albrecht, manufacturers can sometimes strengthen warnings unilaterally through the FDA's "changes being effected" pathway — and claims survive preemption unless there is clear evidence the FDA would have rejected the stronger warning. Judge Marston has framed label adequacy and preemption as cross-cutting questions whose resolution could limit many claims at once. The court's August 2025 opinion also signaled headwinds for pure design-defect theories, since major changes to an approved drug's dosage or formula require FDA preapproval.General Causation and Rule 702 Challenges
The other pivotal question is general causation: whether plaintiffs' experts can reliably show that GLP-1 drugs are capable of causing the alleged injuries, particularly gastroparesis. Plaintiffs' leadership has represented that the vast majority of cases allege gastroparesis, so the court made diagnostic reliability an early cross-cutting issue — if contemporaneous objective testing were required to support a gastroparesis diagnosis, the number and shape of viable claims could change dramatically. The September 2026 Rule 702 hearing is where the court will test the admissibility of the competing expert opinions.Why Bellwether Trials Have Not Started
Unlike many mass torts that move quickly to test trials, Judge Marston front-loaded the science and the law. The court adopted a schedule that resolves expert admissibility and summary judgment on warnings, preemption, and causation before selecting bellwether cases. As of July 2026, no bellwether trial date has been set. Bellwether selection and the first test trials would realistically follow the September 2026 Rule 702 hearing and the summary-judgment rulings — putting any first GLP-1 trial in 2027 at the earliest if the litigation survives those rulings. That sequencing means the MDL's next inflection point is a set of court rulings, not a jury verdict — and those rulings could drastically narrow, reshape, or strengthen the litigation before any case is tried.Current Status and What Happens Next
As of July 4, 2026, the MDL is in the middle of Rule 702 and summary-judgment briefing on preemption, warning adequacy, and general causation. Opening briefs were due May 19, 2026; opposition and reply briefing runs through the summer; and the court has reserved September 10 through 18, 2026 for the Rule 702 hearing. Public status conferences are set roughly monthly through the end of 2026.For people who took Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, the practical takeaways are straightforward. There is no settlement, no certified class, and no claim form — anyone promising a settlement payout right now is not describing this litigation accurately. That said, law firms are actively accepting GLP-1 injury cases: because these are individual injury lawsuits, participating means retaining counsel to file an individual case in the MDL, not submitting a claim form. That distinction is why the docket keeps growing by more than a hundred new lawsuits a month even though there is nothing to "claim." And the rulings expected in late 2026 will likely determine whether the litigation moves toward bellwether trials and eventual resolution, or contracts sharply.
Frequently Asked Questions
What is MDL 3094?MDL No. 3094 is the federal multidistrict litigation in the U.S. District Court for the Eastern District of Pennsylvania covering personal-injury claims alleging that GLP-1 receptor agonist drugs caused gastrointestinal injuries such as gastroparesis. It is captioned In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation and is before Judge Karen Spencer Marston. The claims are unproven allegations; no court has found the manufacturers liable.
Which drugs are included in MDL 3094?
Court materials identify Ozempic, Wegovy, Rybelsus, Victoza, and Saxenda (Novo Nordisk) and Trulicity, Mounjaro, and Zepbound (Eli Lilly) as products within the MDL's operative scope.
How many cases are in MDL 3094?
The Judicial Panel on Multidistrict Litigation's July 1, 2026 statistics report lists 3,848 actions now pending in MDL 3094, up from 3,763 a month earlier. Those are case counts, not docket entry numbers. The MDL began with 37 actions when it was centralized in February 2024 and has grown by more than a hundred new federal filings a month through 2026.
Has there been an Ozempic or GLP-1 settlement in MDL 3094?
No. No settlement has been announced in MDL 3094, no class has been certified, and there is no claim form. The litigation is still in pretrial expert and summary-judgment proceedings, with a Rule 702 hearing scheduled for September 10 through 18, 2026.
Are Ozempic blindness and vision-loss claims part of MDL 3094?
No. In December 2025, the JPML created a separate proceeding, MDL No. 3163, for claims alleging NAION and other vision loss tied to GLP-1 drugs. MDL 3094 covers the gastrointestinal-injury claims. Both MDLs are before Judge Marston in the Eastern District of Pennsylvania.
When could bellwether trials start in the GLP-1 MDL?
No bellwether trial schedule has been publicly set. The court chose to resolve cross-cutting issues first — warning-label adequacy, federal preemption, and general causation — through expert challenges and summary-judgment motions in 2026. Bellwether selection would realistically follow only after those rulings.
Sources
• JPML MDL Statistics Report, June 1, 2026 (PDF) — pending and historical action counts for MDL 3094 and MDL 3163• U.S. Judicial Panel on Multidistrict Litigation — MDL 3094 transfer order and monthly pending-MDL statistics reports
• U.S. District Court, Eastern District of Pennsylvania — MDL 3094 — master docket, case management orders, and the August 15, 2025 memorandum
• U.S. Food & Drug Administration — semaglutide and GLP-1 medication safety information
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
For more class actions keep scrolling below.
Status
Pretrial — Rule 702 & Summary Judgment
Case Title
In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Case Number
MDL No. 3094 (24-md-3094)
Court
U.S. District Court, Eastern District of Pennsylvania
Date Filed
February 2, 2024 (centralized)
Official Website
JPML — MDL 3094
